We then performed immunopeptidomics on eight high-risk diagnostic neuroblastoma primary tumours, focusing on HLA-A*02:01 and HLA-A*24:02 allotypes (Extended Data Table 1 and Supplementary Table 1). This evidence concerns the gene HLA-A and neuroblastoma.